Statin use and EGFR-TKI efficacy in EGFR-mutant non-small cell lung cancer remains to be evaluated
Statins may boost lung cancer treatment, review planned
This protocol for a systematic review and meta-analysis aims to evaluate if statin exposure is associated with improved outcomes in patients…
A new review will examine if statins improve survival in EGFR-mutant lung cancer patients on targeted therapy.
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…